CompletedPHASE2, PHASE3NCT03989531
Adrecizumab in Cardiogenic Shock
Studying Cardiogenic shock
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dr. med. Mahir Karakas
- Principal Investigator
- Mahir Karakas, MD, MBAUniversity Heart Center Hamburg
- Intervention
- Adrecizumab(biological)
- Enrollment
- 150 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2021
Study locations (3)
- University of Berlin, Campus Benjamin-Franklin, Berlin, Germany
- University Heart Center Hamburg, Hamburg, Germany
- University of Ulm, Ulm, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03989531 on ClinicalTrials.govOther trials for Cardiogenic shock
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07527156Prolonged Nasogastric Administration of Ketones in Decompensated Heart FailureInstitute for Clinical and Experimental Medicine
- RECRUITINGNANCT07345559Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic ShockCMC Ambroise Paré
- RECRUITINGNANCT07374289On Scene ECPR in OstravaUniversity Hospital Ostrava
- RECRUITINGNCT07402018Intra-aortic Balloon Counterpulsation (IABC) ComplianceThomas Jefferson University
- RECRUITINGNCT07309029Pre-Emptive LAVA-ECMO for Complex High-Risk TAVRAtlantic Health System
- RECRUITINGNANCT07293923Magenta Elevate™ Clinical Feasibility Study in Cardiogenic ShockMagenta Medical Ltd.
- RECRUITINGNCT07354568Prognosis of Patients With Mixed Cardiogenic-Vasoplegic ShockCentre Hospitalier Universitaire, Amiens
- RECRUITINGNCT06964685Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic ShockAbiomed Inc.